Arcellx

iMMagine-2 Clin2 multiple myeloma; ACLX-001 Clin1 multiple myeloma; ACLX-002 Clin0 AML/MDS; ACLX-003 Clin0 AML/MDS; 4 undisclosed programs RD multiple myeloma, AML, SCLC, hepatocellular carcinoma

Arcellx is developing immunotherapies to treat cancer. Chimeric antigen receptor (CAR) T-cells are the latest innovation to identify and eliminate cancer cells, yet there is still more room for improvement. Arcellx’s unique approach involves their novel D-Domain technology, a small, stable, fully synthetic binding agent that can be combined with CARs to improve target specificity and enhance binding affinity. From the D-Domain, Arcellx can generate diverse libraries of proprietary target-binding domains which serve as the foundation of their proprietary ddCAR and ARC-SparX platforms. Arcellx is currently developing cell therapies treatments for multiple myeloma, acute myeloid leukemia and solid tumors, the first of which is now in Phase 2 clinical trials.